AbbVie’s risankizumab delivers positive results in new psoriasis trials

AbbVie has announced the findings of three clinical trials that demonstrate the strong performance of its new psoriasis therapy risankizumab.

Topline results from the pivotal studies showed that the investigational interleukin-23 inhibitor therapy delivered significantly greater efficacy than standard biologic therapies in the treatment of patients with moderate to severe chronic plaque psoriasis.

In the ultIMMa-1 and ultIMMa-2 trials, risankizumab was shown to achieve significantly higher response rates compared to ustekinumab, while the IMMvent study highlighted the benefits risankizumab can offer compared to adalimumab.

Across all three trials, the drug met its co-primary endpoints and ranked secondary endpoints, highlighting the potential it offers to deliver long-term skin clearance for psoriasis patients.

Dr Michael Severino, executive vice-president for research and development and chief scientific officer at AbbVie, said: "AbbVie is committed to advancing care for patients with immune-mediated diseases. We are building on our two decades of expertise as a leader in immunology to develop a robust portfolio of innovative therapies addressing continued unmet needs."

The drug is being developed in collaboration with Boehringer Ingelheim and has not yet been approved by any regulatory agencies.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.